Skip to the answer

Lacosamide

Lacosamide is an anti-seizure medicine used to treat partial-onset seizures and, as add-on therapy, primary generalized tonic-clonic seizures.

Brand names VimpatMotpolyMotpoly Xr
Drug class Decreased Central Nervous System Disorganized Electrical Activity
Rx Schedule CV Forms 4
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 56 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026 🚨Recall on record · 2
Other forms & routes:
Injection
Lacosamide at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Lacosamide (Vimpat), on the market since about 2008 and available as a generic, is a widely used anti-seizure medicine for partial-onset seizures and, as an add-on, primary generalized tonic-clonic seizures. It helps sodium channels in nerve cells rest longer so they fire less. Most people tolerate it fairly well, though dizziness, double vision and unsteadiness are common, especially as the dose goes up. The thing to watch is your heart rhythm, so get help for fainting, palpitations or a very slow or irregular heartbeat. Also report new depression or suicidal thoughts, and never stop it suddenly, because seizures can return.

Clinical pearls

  • Tell any prescriber adding a beta-blocker, calcium channel blocker or other heart rhythm medicine that you take lacosamide.
  • Motpoly XR capsules are swallowed whole, while the tablets and oral solution can be taken with or without food.
  • As a Schedule V controlled substance, lacosamide may come with tighter refill rules, so ask for refills before you run low.
  • Fever with a rash, swollen glands or facial swelling can signal DRESS, a rare serious drug allergy, and needs urgent care.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asTablet, Oral solution, Injection +1
Earliest FDA record2008
Companies listing it with the FDA56
FDA label last updatedMay 12, 2026
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Lacosamide, written from its FDA label.

What Lacosamide is used for

▾

Lacosamide is used for certain seizure types, depending on the product.

  • Partial-onset seizures: Vimpat and some lacosamide injections from 1 month of age; lacosamide tablets, oral solution and other injections from age 4; Motpoly XR in adults and children weighing at least 50 kg.
  • Add-on therapy for primary generalized tonic-clonic seizures: Vimpat and lacosamide tablets, oral solution and injection from age 4; Motpoly XR in adults and children weighing at least 50 kg.

How Lacosamide works

▾

Lacosamide calms overexcited nerve cells. In lab studies, it enhances slow inactivation of voltage-gated sodium channels, which stabilizes nerve membranes and limits repetitive firing. The exact mechanism in humans is not fully known.

Lacosamide dosage

▾

Dosing depends on the product, and your prescriber will set it for you.

  • Tablets and oral solution (including Vimpat): taken by mouth, usually twice daily, with or without food. Children's doses are based on weight.
  • Motpoly XR: an extended-release capsule taken once daily and swallowed whole with liquid. Do not open, chew or crush it.
  • Injection: given into a vein over 15 to 60 minutes, two or three times daily, only when oral use is temporarily not feasible.
  • Doses are raised no more often than once a week based on response and tolerability.

Dosing details from the FDA-approved label

From the Lacosamide prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Adults (17 years and older) - monotherapy for partial-onset seizures
    • Initial 100 mg twice daily (200 mg per day)
    • Increase by 50 mg twice daily (100 mg per day) every week
    • Maintenance 150 mg to 200 mg twice daily (300 mg to 400 mg per day)
    • Maximum: 200 mg twice daily
    • Severe renal impairment: reduction of 25% of the maximum dosage recommended
  • Adults (17 years and older) - adjunctive therapy for partial-onset seizures or primary generalized tonic-clonic seizures
    • Initial 50 mg twice daily (100 mg per day)
    • Increase by 50 mg twice daily (100 mg per day) every week
    • Maintenance 100 mg to 200 mg twice daily (200 mg to 400 mg per day)
    • Maximum: 200 mg twice daily
    • Severe renal impairment: reduction of 25% of the maximum dosage recommended
  • Adults (17 years and older) - alternate initial dosing regimen for week 1
    • Single loading dose: 200 mg
    • 12 hours later initiate 100 mg twice daily (200 mg per day)
    • Increase by 50 mg twice daily (100 mg per day) at weekly intervals, if needed
    • Loading dose should be given with medical supervision; continue alternate regimen for one week
  • Pediatric patients weighing at least 50 kg
    • Initial 50 mg twice daily (100 mg per day)
    • Increase by 50 mg twice daily (100 mg per day) every week
    • Maintenance monotherapy 150 mg to 200 mg twice daily (300 mg to 400 mg per day), adjunctive 100 mg to 200 mg twice daily (200 mg to 400 mg per day)
    • Increase no more frequently than once per week
  • Pediatric patients weighing 30 kg to less than 50 kg
    • Initial 1 mg/kg twice daily (2 mg/kg/day)
    • Increase by 1 mg/kg twice daily (2 mg/kg/day) every week
    • Maintenance 2 mg/kg to 4 mg/kg twice daily (4 mg/kg/day to 8 mg/kg/day)
    • Dosing depends on body weight
  • Pediatric patients weighing 11 kg to less than 30 kg
    • Initial 1 mg/kg twice daily (2 mg/kg/day)
    • Increase by 1 mg/kg twice daily (2 mg/kg/day) every week
    • Maintenance 3 mg/kg to 6 mg/kg twice daily (6 mg/kg/day to 12 mg/kg/day)
    • Dosing depends on body weight
  • Pediatric patients weighing 6 kg to less than 11 kg and less than 6 kg (partial-onset seizures only)
    • Oral: 1 mg/kg twice daily (2 mg/kg/day)
    • Increase by 1 mg/kg twice daily (2 mg/kg/day) every week
    • Maintenance 3.75 mg/kg to 7.5 mg/kg twice daily (7.5 mg/kg/day to 15 mg/kg/day)
    • Indicated only for partial-onset seizures
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Adults (17 years and older): Initial dosage for monotherapy for the treatment of partial-onset seizures is 100 mg twice daily ( 2.1 ) Initial dosage for adjunctive therapy for the treatment of partial-onset seizures or primary generalized tonic-clonic seizures is 50 mg twice daily ( 2.1 ) Maximum recommended dosage for monotherapy and adjunctive therapy is 200 mg twice daily ( 2.1 ) Pediatric Patients 1 month to less than 17 years : The recommended dosage is based on body weight and is administered orally twice daily ( 2.1 ) Increase dosage based on clinical response and tolerability, no more frequently than once per week ( 2.1 ) Injection: for intravenous use only when oral administration is temporarily not feasible; the recommended dosage is based on body weight and is administered two or three times daily over 15 to 60 minutes; obtaining ECG before initiation is recommended in certain patients ( 2.7 , 5.3 ) Dose adjustment is recommended for severe renal impairment ( 2.4 , 12.3 ) Dose adjustment is recommended for mild or moderate hepatic impairment; use in patients with severe hepatic impairment is not recommended ( 2.5 , 12.3 ) 2.1 Dosage Information The recommended dosage for monotherapy and adjunctive therapy for partial-onset seizures in patients 1 month of age and older and for adjunctive therapy for primary generalized tonic-clonic seizures in patients 4 years of age and older is included in Table 1. In pediatric patients, the recommended dosing regimen is dependent upon body weight. Dosage should be increased based on clinical response and tolerability, no more frequently than once per week. Titration increments should not exceed those shown in Table 1. Table 1: Recommended Dosages for Partial-Onset Seizures (Monotherapy or Adjunctive Therapy) in Patients 1 Month and Older, and for Primary Generalized Tonic-Clonic Seizures (Adjunctive Therapy) in Patients 4 Years of Age and Older when not specified, the dosage is the same for monotherapy for partial-onset seizures and adjunctive therapy for partial-onset seizures or primary generalized tonic-clonic seizures. Oral and intravenous dosages are the same unless specified.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Lacosamide side effects

▾

Most side effects are related to the nervous system and digestion.

Common side effects

  • Dizziness
  • Headache
  • Double vision (diplopia)
  • Nausea
  • Sleepiness (somnolence)
  • Poor balance or coordination (ataxia)
  • Vomiting
  • Blurred vision

When to get medical help

  • Call your doctor right away about new or worsening depression, suicidal thoughts, or unusual mood or behavior changes.
  • Get help for fainting, a very slow or irregular heartbeat, or palpitations.
  • Seek urgent care for fever, rash, swollen glands or facial swelling, which may signal a serious allergic reaction (DRESS).
  • Tell your doctor if dizziness or poor balance gets worse, especially when your dose is raised.
  • Do not stop suddenly. Seizures may become more frequent.

Seek help for heart rhythm symptoms, fainting, mood changes or suicidal thoughts, or fever with rash or swelling.

Lacosamide warnings and precautions

▾
  • Suicidal thoughts: anti-seizure drugs slightly raise this risk. Watch for new or worsening depression or mood changes.
  • Dizziness and poor balance: most common when starting or raising the dose, and more likely above the recommended doses.
  • Heart rhythm problems: PR interval lengthening, AV block, slow heartbeat and, rarely, serious arrhythmias. Atrial fibrillation or flutter have also been reported.
  • Fainting: reported, particularly in people with heart risk factors.
  • DRESS: a rare, sometimes life-threatening allergic reaction. Stop and get evaluated if signs appear.
  • Stopping: taper over at least a week.

Lacosamide interactions

▾

Medicines that affect the heart or blood levels of lacosamide need care.

  • Sodium channel blockers (including some anti-seizure drugs): may add to heart conduction effects.
  • Beta-blockers, calcium channel blockers, potassium channel blockers: may raise the risk of AV block, slow heartbeat or dangerous rhythms.
  • Other PR-lengthening medicines: further PR prolongation is possible.
  • Strong CYP3A4 or CYP2C9 inhibitors: can raise lacosamide levels in people with kidney or liver impairment.

Interactions listed in the FDA-approved label

From the Lacosamide prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Strong inhibitors of CYP3A4 and CYP2C9: Patients with renal or hepatic impairment taking these may have a significant increase in exposure to lacosamide. Dose reduction may be necessary in these patients.
  • Concomitant medications that affect cardiac conduction (sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers), including those that prolong PR interval (including sodium channel blocking AEDs): Risk of AV block, bradycardia, or ventricular tachyarrhythmia. Use with caution; obtain an ECG before beginning lacosamide and after it is titrated to steady-state; monitor closely if given intravenously.
Read the label’s full interactions text

7 DRUG INTERACTIONS 7.1 Strong CYP3A4 or CYP2C9 Inhibitors Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to lacosamide. Dose reduction may be necessary in these patients. 7.2 Concomitant Medications that Affect Cardiac Conduction Lacosamide should be used with caution in patients on concomitant medications that affect cardiac conduction (sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers) including those that prolong PR interval (including sodium channel blocking AEDs), because of a risk of AV block, bradycardia, or ventricular tachyarrhythmia. In such patients, obtaining an ECG before beginning lacosamide, and after lacosamide is titrated to steady-state, is recommended. In addition, these patients should be closely monitored if they are administered lacosamide through the intravenous route [see Warnings and Precautions ( 5.3 )] .

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿151 supplements and herbs with documented Lacosamide interactions, ranked by severity Check Lacosamide against a supplement or herb →

Before taking Lacosamide

▾
  • No contraindications are listed on the label.
  • Tell your doctor about heart conduction problems, heart failure or other heart disease.
  • Kidney problems: the dose is adjusted for severe impairment.
  • Liver problems: the dose is adjusted for mild or moderate impairment, and use is not recommended in severe impairment.
  • Pregnancy: animal data suggest possible harm; human data are limited. A pregnancy registry is available.
  • Breastfeeding: the drug passes into milk; watch the baby for excess sleepiness.
  • Older adults: dosing is started cautiously.
  • Children: age limits depend on the product.

Lacosamide overdose

▾

Taking too much can cause dizziness, nausea, seizures, confusion, reduced alertness, heart conduction problems, cardiac arrest and coma. Deaths have occurred with overdoses of several grams. There is no specific antidote, so call Poison Control or emergency services. Care is supportive, and hemodialysis may help clear the drug.

What Lacosamide does in the body

▾

Higher lacosamide levels in the body are linked with fewer seizures, but doses above 400 mg/day did not appear to add benefit. Lacosamide causes a small, dose-related lengthening of the PR interval on an ECG. It did not lengthen the QTc interval in a trial of healthy volunteers.

How your body processes Lacosamide

▾

Lacosamide is absorbed almost completely when taken by mouth, and food does not affect absorption. Levels peak about 1 to 4 hours after a dose, and the half-life is about 13 hours. Steady levels are reached after about 3 days of twice-daily dosing. The kidneys clear most of it, partly unchanged. Kidney or moderate liver impairment raises drug levels.

How to store Lacosamide

▾

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Do not freeze VIMPAT injection or oral solution.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

151

Supplements & herbs that interact with Lacosamide

151 supplements and herbal products have documented interactions with Lacosamide in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 3
  • Moderate · 107
  • Minor · 41
ACTIVATED CHARCOAL Major GRAPEFRUIT Major ST. JOHN'S WORT Major ACACIA RIGIDULA Moderate ADRAFINIL Moderate AFRICAN WILD POTATO Moderate AMERICAN ELDER Moderate ASTAXANTHIN Moderate +143 more
Every supplement checked against Lacosamide — ranked by severity The full interaction hub: 3 major · 107 moderate · 41 minor · every one linked to its full report. Check Lacosamide against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Lacosamide: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Lacosamide — the kind of thing our pharmacy team would talk through with you at the counter.

What is lacosamide used for?

▾
It treats partial-onset seizures, and it is also used as add-on treatment for primary generalized tonic-clonic seizures. Which age groups it covers depends on the product, so your pharmacist can confirm yours.

How should I take it?

▾
Tablets and oral solution are usually taken twice a day, with or without food. Motpoly XR is a once-daily capsule that you swallow whole, without opening, chewing or crushing. Follow your prescriber's directions.

What side effects should I expect?

▾
Dizziness is the big one, along with headache, double or blurry vision, nausea, sleepiness and balance trouble. These are most noticeable when starting or raising the dose. Tell your doctor if they bother you or get worse.

When should I call my doctor?

▾
Call right away for fainting, a very slow or irregular heartbeat, or new or worsening depression or suicidal thoughts. Also call for fever with rash or swelling, which can be a serious allergic reaction.

Can I stop it if I feel fine?

▾
No. Stopping suddenly can bring seizures back or make them more frequent. Your prescriber will taper it over at least a week.

Is it safe in pregnancy or while breastfeeding?

▾
Human data are limited, and animal studies showed possible harm. Talk with your doctor before planning pregnancy, and ask about the pregnancy registry. The drug passes into breast milk, so watch your baby for extra sleepiness.

Is Lacosamide available over the counter?

▾
No. Lacosamide is a prescription medicine: every Lacosamide product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

Is Lacosamide a controlled substance?

▾
Yes — Lacosamide is a federally controlled substance (Schedule V) in the United States, so how it is prescribed, refilled and dispensed is regulated by the DEA.

When was Lacosamide first available?

▾
The earliest FDA record we hold for Lacosamide is from 2008: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Lacosamide was first used.

Who makes Lacosamide?

▾
56 companies currently list Lacosamide products in the FDA's NDC Directory, including Camber Pharmaceuticals, Inc., Major Pharmaceuticals, NorthStar RxLLC. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Lacosamide on HelloPharmacist

📊Lacosamide supplement interactions151 checked — ranked by severity 🌿Drug & Supplement CheckerLacosamide vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Lacosamide NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Lacosamide Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Lacosamide forms and strengths (how it comes)

Lacosamide is available in 4 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
Brands Vimpat
How this form is used
What it may be used for
  • Lacosamide tablets treat partial-onset seizures in patients 4 years and older.
  • Lacosamide tablets are add-on therapy for primary generalized tonic-clonic seizures in patients 4 years and older.
  • Vimpat is labeled for partial-onset seizures from 1 month of age.
Important instructions
  • Lacosamide tablets are taken by mouth twice daily.
  • In children, Lacosamide tablet dosing is based on body weight.
Available strengths 4 strengths
50 mg 100 mg 150 mg 200 mg
235 FDA-listed product records ⓘ

Oral solution

By mouth
Brands Vimpat
How this form is used
What it may be used for
  • Lacosamide oral solution treats partial-onset seizures in patients 4 years and older.
  • Lacosamide oral solution is add-on therapy for primary generalized tonic-clonic seizures in patients 4 years and older.
  • Vimpat is labeled for partial-onset seizures from 1 month of age.
Important instructions
  • Lacosamide oral solution is taken by mouth twice daily.
  • In children, Lacosamide oral solution dosing is based on body weight.
Available strengths 6 strengths
10 mg/mL 50 mg/5 mL 100 mg/10 mL 150 mg/15 mL 200 mg/20 mL 1 kg/kg
46 FDA-listed product records ⓘ

Injection

By injection · Into a vein
Brands Vimpat
How this form is used
What it may be used for
  • Vimpat treats partial-onset seizures from 1 month of age and is add-on therapy for primary generalized tonic-clonic seizures from age 4.
  • Lacosamide injection is labeled for partial-onset seizures and add-on treatment of primary generalized tonic-clonic seizures; the age range depends on the specific product label.
Important instructions
  • Vimpat injection is for intravenous use only when oral use is temporarily not feasible.
  • Vimpat injection is given two or three times daily over 15 to 60 minutes.
  • An ECG before starting Vimpat injection is recommended in certain patients.
Available strengths 2 strengths
10 mg/mL 200 mg/20 mL
45 FDA-listed product records ⓘ

Extended-release capsule

By mouth
Brands Motpoly Xr
How this form is used
What it may be used for
  • Motpoly XR treats partial-onset seizures in adults and children weighing at least 50 kg.
  • Motpoly XR is add-on therapy for primary generalized tonic-clonic seizures in adults and children weighing at least 50 kg.
Important instructions
  • Motpoly XR is taken once daily.
  • Motpoly XR capsules should be swallowed whole with liquid.
  • Do not open, chew or crush Motpoly XR capsules.
Available strengths 3 strengths
100 mg 150 mg 200 mg
9 FDA-listed product records ⓘ

Lacosamide on the U.S. market: products, makers and brands

How Lacosamide appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

56 companies list 162 Lacosamide product records with the FDA, mostly as tablet, oral solution, injection; the earliest marketing or approval year on record is 2008. Brand names on the directory include Vimpat, Motpoly, Motpoly Xr; the rest are generics.

4
Dose forms ⓘ
56
Labelers (makers, repackagers, distributors)
4
Brand names
162
FDA-listed product records ⓘ
2008
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (25) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Camber Pharmaceuticals, Inc.4%
Major Pharmaceuticals4%
NorthStar RxLLC4%
Remedyrepack Inc.4%
UCB, Inc.4%
Ascend Laboratories, LLC3%
Other makers78%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Lacosamide is used (Medicaid data)

A general measure of how commonly Lacosamide is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Lacosamide is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

735,538
Medicaid prescriptions filled (Q1–Q4 2025)
$81.6M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Lacosamide prescribed? Of the 1,601 medications we measure, Lacosamide ranks #211 by Medicaid prescriptions — more than 87% of them.

Where Lacosamide ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #211 of 1,601
#206 Atenolol 765,683 Rx #207 Calcium Chloride / Pot... 764,836 Rx #208 Dupilumab Injection 758,467 Rx #209 Rizatriptan 745,530 Rx #210 Tiotropium Oral Inhala... 739,246 Rx #211 Lacosamide 735,538 Rx #212 Acyclovir 733,721 Rx #213 Testosterone 731,644 Rx #214 Progesterone 725,527 Rx #215 Sucralfate 724,768 Rx #216 Ketotifen Ophthalmic 714,559 Rx

Utilization by Lacosamide product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 200 mg oral tablet is the most-dispensed Lacosamide product — about 31% of these Medicaid prescriptions.

lacosamide 200 MG Oral Tablet Most dispensed

224,908 Medicaid prescriptions (Q1–Q4 2025) 31% of Lacosamide prescriptions shown $26M gross reimbursement (before rebates) ≈ $116 per prescription (gross)

Summed across the 16 of 70 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 809996

lacosamide 100 MG Oral Tablet

174,506 Medicaid prescriptions (Q1–Q4 2025) 24% of Lacosamide prescriptions shown $13.4M gross reimbursement (before rebates) ≈ $77 per prescription (gross)

Summed across the 18 of 71 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 809987

lacosamide 10 MG/ML Oral Solution

149,036 Medicaid prescriptions (Q1–Q4 2025) 20% of Lacosamide prescriptions shown $25.3M gross reimbursement (before rebates) ≈ $170 per prescription (gross)

Summed across the 10 of 84 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 993856

lacosamide 150 MG Oral Tablet

98,198 Medicaid prescriptions (Q1–Q4 2025) 13% of Lacosamide prescriptions shown $9.1M gross reimbursement (before rebates) ≈ $92 per prescription (gross)

Summed across the 15 of 64 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 809992

lacosamide 50 MG Oral Tablet

86,345 Medicaid prescriptions (Q1–Q4 2025) 12% of Lacosamide prescriptions shown $5.1M gross reimbursement (before rebates) ≈ $59 per prescription (gross)

Summed across the 16 of 74 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 810000

24 HR lacosamide 200 MG Extended Release Oral Capsule

1,282 Medicaid prescriptions (Q1–Q4 2025) <1% of Lacosamide prescriptions shown $1.5M gross reimbursement (before rebates) ≈ $1,162 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2637032

24 HR lacosamide 150 MG Extended Release Oral Capsule

485 Medicaid prescriptions (Q1–Q4 2025) <1% of Lacosamide prescriptions shown $605,618 gross reimbursement (before rebates) ≈ $1,249 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2637027

24 HR lacosamide 100 MG Extended Release Oral Capsule

413 Medicaid prescriptions (Q1–Q4 2025) <1% of Lacosamide prescriptions shown $455,090 gross reimbursement (before rebates) ≈ $1,102 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2637018

20 ML lacosamide 10 MG/ML Injection

365 Medicaid prescriptions (Q1–Q4 2025) <1% of Lacosamide prescriptions shown $178,506 gross reimbursement (before rebates) ≈ $489 per prescription (gross)

Summed across the 6 of 44 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 809974

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Lacosamide, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 84 of 411 listed Lacosamide NDCs with Medicaid activity.

Compare Lacosamide products

A representative set of FDA-listed product records for Lacosamide — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 99 of 162 products — FDA National Drug Code Directory. See every product, package size and price: browse all 162 Lacosamide NDCs →

Lacosamide side effects reported to the FDA (FAERS)

After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Lacosamide — a signal of what to watch for, not proof the drug caused it.

The effects most often named in FDA reports that mention Lacosamide are seizure, dizziness, somnolence; about 79% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.

36,995
Reports mentioning it
79%
Reported as serious
12
Distinct effects shown
Most reported effects
Seizure
6,858
Dizziness
1,669
Somnolence
1,496
Fatigue
1,446
Epilepsy
1,417
Fall
1,395
Overdose
1,279
Status Epilepticus
1,276
Generalised Tonic-clonic Seizure
1,197
Death
1,071
Age groups
Adult · 2,071Elderly · 709Neonate · 328Child · 299Adolescent · 158Infant · 111

Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Lacosamide in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.

Lacosamide FDA approval history

How Lacosamide went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.

Lacosamide was first approved by the FDA in 2008 (Brand: VIMPAT · Ucb Inc); the first generic version was approved in 2022. It remains available in U.S. pharmacies today.

2008
Brand approved
Brand: VIMPAT · Ucb Inc
2022
First generic approved
Lower-cost ANDA competition begins
2026
Available today
Active in U.S. pharmacies

Source: Drugs@FDA.

Lacosamide recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list 3 Lacosamide recalls since July 2021, covering 6 product listings. Two of them are still ongoing or began in the last six months and are listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Ongoing Class II Jun 4, 2026 · Annora Pharma Private Limited
Presence of a Foreign Tablets: Complaint received, possible mix-up of Selexipag 1000 mcg tablet in a bottle of Lacosamide Tablets USP, 100mg.
  • Lacosamide Tablets, USP, C V, 100mg, Rx only, 60-count bottle, By: Annora Pharma Pvt., Ltd, Sangareddy -502313, Telangana, India, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854,… Lots: Lot: A253999, A254000, Expires: 09/30/2027. FDA record D-0626-2026 →
Ongoing Class II Mar 13, 2025 · Glenmark Pharmaceuticals Inc., USA
CGMP Deviations
  • Lacosamide Tablets 150mg, 60-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc. USA, Ma… Lots: Lot # 17241125, exp. date Jun-26 17242202, exp. date Nov-26 17242204, exp. date Dec-26 FDA record D-0343-2025 →
  • Lacosamide Tablets, 50mg, 60-count bottles, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc. USA, M… Lots: Lot # 17240221, exp. date Jan-26 17240222, exp. date Jan-26 FDA record D-0337-2025 →
  • Lacosamide Tablets, 100mg , 60-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc. USA,… Lots: Lot # 17232533, exp. date Nov-25 17232534, exp. date Nov-25 17240606, exp. date Mar-26 17240619, exp. date Mar-26 17240911, exp. date May-26 17240912, exp. date May-26 17241121, exp. date Jun-26 17241124, exp. date Jun-26 FDA record D-0330-2025 →
  • Lacosamide Tablets 200mg, 60-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc. USA, Ma… Lots: Lot # 17230982, exp. date Apr-25 17230986, exp. date, Apr-25 17231001, exp. date, Apr-25 17240197, exp. date Jan-26 17240198, exp. date Jan-26 17240215, exp. date Jan-26 17240846, exp. date Apr-26 17240847, exp. date Apr-26 FDA record D-0321-2025 →
Class III Dec 6, 2022 · Terminated · Camber Pharmaceuticals, Inc
Failed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid content
  • Lacosamide Oral Solution, USP, CV, 10mg/mL, packaged in 200 mL bottle, Rx Only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, Manufactured By: HETERO LABS LIMITED, Jeedimetla,… Lots: Lot#: E222200, E222199, Exp 05/2024; E222228, Exp 06/2024 FDA record D-0094-2023 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Lacosamide RxCUI 623400 4 dose forms · 9 strengths
  2. Dose form (SCDF) Injection RxCUI 1734184 In current FDA listings
    Clinical drug / strength (SCD) 20 ML lacosamide 10 MG/ML RxCUI 809974
  3. Dose form (SCDF) Oral Solution RxCUI 993855 In current FDA listings
    Clinical drug / strength (SCD) 10 MG/ML RxCUI 993856
  4. Dose form (SCDF) Oral Tablet RxCUI 809986 In current FDA listings
    Clinical drug / strength (SCD) 50 MG RxCUI 810000 100 MG RxCUI 809987 150 MG RxCUI 809992 200 MG RxCUI 809996

Look up RxCUI 623400 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Lacosamide costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Tablet, Film Coated · Oral 100 mg $18.54 per tablet NDC details & price history
Tablet, Film Coated · Oral 50 mg $11.82 per tablet NDC details & price history
Tablet, Film Coated · Oral 200 mg $19.63 per tablet NDC details & price history
Tablet, Film Coated · Oral 150 mg $19.65 per tablet NDC details & price history
Solution · Oral 10 mg/mL $1.98–$2.30 per mL NDC details & price history
Solution · Oral 200 mg/20 mL $0.083 per mL NDC details & price history
Tablet · Oral 50 mg $0.119 per tablet NDC details & price history
Tablet · Oral 100 mg $0.174 per tablet NDC details & price history
Tablet · Oral 150 mg $0.221 per tablet NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Lacosamide brand names

Lacosamide is sold under 3 brand names in the FDA directory — Vimpat, Motpoly, Motpoly Xr. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Vimpat Motpoly Motpoly Xr

Who makes Lacosamide: manufacturers and labelers

56 companies list Lacosamide products with the FDA. By number of product records, the largest are Camber Pharmaceuticals, Inc., Major Pharmaceuticals, NorthStar RxLLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Camber Pharmaceuticals, Inc. 6 Major Pharmaceuticals 6 NorthStar RxLLC 6 Remedyrepack Inc. 6 UCB, Inc. 6 Ascend Laboratories, LLC 5 Aurobindo Pharma Limited 5 Florida Pharmaceutical Products, LLC 5 Glenmark Pharmaceuticals Inc. USA 5 Indoco Remedies Limited 5 Kanchan Healthcare Inc 5 Westminster Pharmaceuticals, LLC 5 Alembic Pharmaceuticals Inc. 4 Alembic Pharmaceuticals Limited 4 American Health Packaging 4 Amneal Pharmaceuticals of New York LLC 4 Breckenridge Pharmaceutical, Inc. 4 Clinical Solutions Wholesale, LLC 4 Golden State Medical Supply, Inc. 4 Msn Laboratories Private Limited 4 Macleods Pharmaceuticals Limited 4 Marlex Pharmaceuticals, Inc 4 PAI Holdings, LLC dba PAI Pharma 4 Proficient Rx LP 4

…and 32 more on the FDA NDC directory.

Lacosamide drug class (RxNorm)

Lacosamide belongs to the Other antiepileptics class.

Drug family (ATC) Other antiepileptics

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Lacosamide page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective May 12, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Lacosamide.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Lacosamide after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
56
Finished products in the current FDA directory
162
Companies listing them (makers, repackagers, distributors)
56
FDA labeler codes behind them ⓘ
56
Linked representative label ⓘ
UCB, Inc.
Linked label effective
May 12, 2026
Composite sections available
25
Linked SPL Set ID
9e79b42c-38a3-4b2c-a196-a5a1948250e2
Linked SPL Document ID
51a12988-3e4b-c52b-e063-6394a90a7415
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. UCB, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →